DENVER, CO—Longer-term follow-up data from the ABSORB II and III trials confirm the significantly increased risk of thrombotic events with the Absorb bioresorbable vascular scaffold (BVS; Abbott ...
WASHINGTON, DC—Three-year outcomes from the ABSORB II trial, a time point in which the Absorb GT1 bioresorbable vascular scaffold should be degraded, did not result in an improvement in vasomotor tone ...
Abbott said it will monitor bioabsorbable stent implantations in Europe, following a high rate of heart attacks in European Absorb GT1 patients, plus a separate FDA safety alert regarding adverse ...
Abbott Laboratories, one of the biggest makers of coronary stents in the world, is halting global sales of a fully absorbable stent that was once hailed as the next big breakthrough in medical devices ...
Little more than a year after receiving FDA approval for its Absorb Bioresorbable Vascular Scaffold (BVS), Abbott has announced it will stop selling the device. The worldwide discontinuation of sales, ...
CALGARY, Alberta--(BUSINESS WIRE)--Absorb Software Inc., a leading provider of cloud-based learning and performance management software for corporations and higher education institutions, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results